Phase I-B trial of the radiosensitizer: Etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02)
Phase I-B trial of the radiosensitizer: Etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02)
复制标题
DOI：
10.1016/j.radonc.2008.02.006
复制
发表时间：
2008-04-01
影响因子：
5.7
通讯作者：
Souhami, L.
中科院分区：
文献类型：
--
作者：
Drzymala, R. E.;Wasserman, T. H.;Souhami, L.
RTOG 95-02 评估了患者对缺氧细胞放射增敏剂依他硝唑 (SR-2508) 联合放射外科的耐受性。患者患有原发性或转移性脑肿瘤并且之前接受过局部或全脑照射。根据肿瘤大小，报告了三组患者的毒性。 12 g/m(2) 依托硝唑剂量联合放射外科治疗耐受性良好。 (C) 2008 Elsevier Ireland Ltd. 保留所有权利。
RTOG 95-02 assessed patient tolerance to hypoxic cell radiosensitizer, etanidazole (SR-2508), combined with radiosurgery. Patients had primary or metastatic brain tumors and previously localized or whole brain irradiation. The toxicity is reported in three groups of patients according to the tumor size. Etanidazole doses of 12 g/m(2) combined with radiosurgery were well tolerated. (C) 2008 Elsevier Ireland Ltd. All rights reserved.